Cognizant (CTSH) announced it is working with Boehringer Ingelheim to advance the speed and quality of medicinal therapy development. Leveraging the Veeva (VEEV) Development Cloud, Cognizant will help Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions. Cognizant initiated the Boehringer Ingelheim engagement with an analysis of the biopharmaceutical manufacturer’s business and technology, followed by development of the program roadmap and agile methodology for system integration. Collaborating with Veeva, Cognizant is now implementing services, which include program management, system architecture and design, training, data migration, integration, testing and validation services.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTSH: